Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
Lymphomas are divided into Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL), together affecting 80 000 US patients.1 Although most patients with HL are cured with initial chemotherapy with or without radiation, curability depends on disease subtype and prognostic parameters. Non-Hodgkin lymphoma is categorized into indolent and aggressive subtypes; diffuse large B-cell lymphoma (DLBCL) is most common and the prototype of aggressive histologies. About 15% to 20% of patients with HL and 30% to 40% of patients with DLBCL relapse after initial therapy.1 Patients relapsing with HL and DLBCL are offered autologous stem cell transplantation, which can cure approximately 40% of DLBCL and 50% to 70% of HL.1
Nabhan C, Smith SM, Cifu AS. Surveillance Imaging in Patients in Remission From Hodgkin and Diffuse Large B-Cell Lymphoma. JAMA. 2016;315(19):2115-2116. doi:10.1001/jama.2016.4913